Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 22nd June 2016
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Project to reduce use of animals in vaccine production
Lab mouse
The project could significantly reduce the use of animals in routine vaccine production.
VAC2VAC takes One Health approach to replacing traditional testing methods 

A project which could significantly reduce the use of animals in routine vaccine production will unite some of Europe’s largest pharmaceutical companies.

Funded by the Innovative Medicines Initiative (IMI2), the VAC2VAC project aims to provide data to support the ‘Consistency Approach’ for quality control of vaccines.  Currently, quality control for final products relies on in vivo methods.

A host of organisations from veterinary and human vaccine industry are collaborating in the project, including Zoetis, GlaxoSmithKlein (GSK) and Merial.

To achieve their goal, the organisations will develop, optimise and evaluate physicochemical and immunochemical methods, cell-based and other assays for routine batch quality, safety and efficacy testing of vaccines. This will be done in collaboration and consultation with regulatory agencies.

Noting the importance of this project, Denis Lambrigts from GSK said: “The VAC2VAC project provides a unique platform to support the transition away from in vivo batch release testing for vaccines.

“It brings together both the human and veterinary pharmaceutical industry along with academia and regulators, to build a platform for the development, validation and regulatory acceptance of alternative approaches.

“For industry this is a very positive One Health approach to the challenge of replacement of the long established in vivo test methods and all companies involved are committed to the success off this project.”

Prof. Conrad Hendriksen from Intravacc, one of the key promoters of the project, added: “VAC2VAC takes into account both vaccine safety and animal welfare.

“It will allow us to move away from the traditional paradigm of vaccine batch release testing and to accelerate the introduction of a new paradigm based on innovative non-animal techniques”.

The project is expected to end in 2021 at a total cost of €15.98 million. 

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
New form for online veterinary medicines retailers

The Veterinary Medicines Directorate (VMD) has produced a new online form for retailers wishing to sell veterinary medicines on the internet.

The form replace the previous Word version and is part of the VMD's ongoing commitment to digitise its processes. Anyone retailing prescription medicines online, including POM-V, POM-VPS and NFA-VPS categories, is lawfully required to register with the VMD before trading.

The change only applies to new applicants. Retailers already listed on the VMD's Register of Online Retailers or registered under the Accredited Internet Retailer Scheme (AIRS) do not need to do anything.